High-Dose Selegiline in Treatment-Resistant Older Depressive Patients

Sunderland, Trey; Cohen, Robert M.; Molchan, Susan E.; Lawlor, Brian A.; Mellow, Alan M.; Newhouse, Paul; Tariot, Pierre N.; Mueller, Edward A.; Murphy, Dennis L.

doi:10.1001/archpsyc.1994.03950080019003

Cited by 112 publications

(53 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings suggest that the ACTH-treated rats may serve as an animal model for tricyclic antidepressant treatmentresistant depressive conditions. The use of selegiline has been reported to improve the response to various antidepressants in otherwise treatment-resistant patients (6,7). In the present study, the immobility-decreasing effect suggests that selegiline may be effective against tricyclic antidepressant treatment-resistant depression.…”

Section: Discussionsupporting

confidence: 54%

“…It has been reported that the anti-Parkinson drug selegiline, a selective and irreversible monoamine oxidase (MAO)-B inhibitor, is effective against treatment-resistant depression (6,7). There is increasing evidence that impaired functioning of the mesolymbic dopaminergic system is involved in the pathogenesis of depression, while a common property of antidepressant drugs is their ability to reinforce the dopaminergic system (8).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Selegilin Exerts Antidepressant-Like Effects During the Forced Swim Test in Adrenocorticotropic Hormone–Treated Rats

et al. 2008

View full text Add to dashboard Cite

Abstract. In the present study, we investigated the effect of adrenocorticotropic hormone (ACTH) on the immobilization of rats in the forced swim test after the administration of selegiline, a selective and irreversible monoamine oxidase (MAO)-B inhibitor. Single and repeated administration of selegiline significantly decreased the duration of immobility in normal rats. When selegiline was administered for 15 days, we observed a significant decrease in immobility in rats treated with ACTH for 14 days. The immobility-decreasing effect of selegiline was blocked by nafadotride, a selective dopamine D 3 -receptor antagonist in normal and ACTHtreated rats. Selegiline may be useful in an animal model of depressive conditions resistant to tricyclic antidepressant treatment via the dopamine D 3 receptor.

show abstract

Section: Discussionsupporting

confidence: 54%

Section: Introductionmentioning

confidence: 99%

Selegilin Exerts Antidepressant-Like Effects During the Forced Swim Test in Adrenocorticotropic Hormone–Treated Rats

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In fact, the best evidence of antidepressant efficacy comes from studies employing larger, nonselective dosages (i.e., 20-50 mg/day) of L-selegiline (e.g., Mann et al 1989;Sunderland et al 1994). This suggests that inhibition of type A enzyme, either alone or in combination with inhibition of MAO Type B, is critical to the MAOIs' antidepressant response .…”

Section: Pharmacologymentioning

confidence: 99%

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Lotufo-Neto

1999

Neuropsychopharmacology

146

View full text Add to dashboard Cite

“…116,117 Subjects in these highdose selegiline trials were maintained on low tyramine or strict MAOI diets. [115][116][117] Case reports and studies have also described the use of MAOIs in combination with other antidepressants, including bupropion with tranylcypromine, RIMAs with SSRIs, and irreversible MAOIs with TCAs. 118-120 The current safety data concerning such combinations are limited and clinicians must exercise appropriate caution.…”

Section: Treatment-refractory Depressionmentioning

confidence: 99%

The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice

Fiedorowicz

Swartz

2004

Journal of Psychiatric Practice

139

View full text Add to dashboard Cite

The use of monoamine oxidase inhibitors (MAOIs) by psychiatrists has declined over the past several decades with the expansion of psychiatrists' pharmacologic armamentarium. This trend has also been driven by concern about food and drug interactions and side effects, as well as waning physician experience with these medications. Many psychiatrists, in fact, never prescribe MAOIs. Recent research has liberalized the MAOI diet and identified symptom presentations more likely to respond to these medications. Thus, clinicians must continue to familiarize themselves with the properties of and indications for prescribing MAOIs. Keywords psychopharmacology; drug response; monoamine oxidase inhibitors (MAOIs); phenelzine; isocarboxazid; tranylcypromine; moclobemide; selegiline; dosage; physician prescribing practices; major depression; bipolar depression; atypical depression; treatment-refractory depression CURRENTLY AVAILABLE MONOAMINE OXIDASE INHIBITORSThe nonselective monoamine oxidase inhibitors (MAOIs) currently available in the United States include phenelzine (Nardil), isocarboxazid (Marplan), and tranylcypromine (Parnate). These medications are irreversible inhibitors of the enzyme monoamine oxidase (MAO).Selegeline is a selective inhibitor of type B MAO (MAO B ) and is currently approved by the United States Food and Drug Administration for parkinsonism. Current studies using selegeline for depression are discussed at the end of this article in the section on "Future Directions."Moclobemide is a reversible inhibitor of type A MAO (MAO A ) and is consequently believed to require fewer dietary restrictions.

show abstract

High-Dose Selegiline in Treatment-Resistant Older Depressive Patients

Cited by 112 publications

References 57 publications

Selegilin Exerts Antidepressant-Like Effects During the Forced Swim Test in Adrenocorticotropic Hormone–Treated Rats

Selegilin Exerts Antidepressant-Like Effects During the Forced Swim Test in Adrenocorticotropic Hormone–Treated Rats

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice

Contact Info

Product

Resources

About